Erratum: Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients (Modern Pathology (2009) 22 (786-796) DOI: 10.1038/modpathol.2009.29);Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients

Modern Pathology

Volumn 22, Issue 6, 2009, Pages 786-796

  Zhao, Liang ^a   Wang, Hui ^b   Deng, Yong Jian ^a   Wang, Shuang ^a   Liu, Chao ^a   Jin, He ^a   Ding, Yan Qing ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Colorectal cancer; DNA methylation; Poor prognosis; Proteomics; Transgelin

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA ACTIN; BIOLOGICAL MARKER; TRANSGELIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA METHYLATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT INFORMATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 67349223633     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.144     Document Type: Erratum

References (40)

1. Tan S, Seow TK, Liang RC, et al. Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int J Cancer 2002;98:523-531.
2. You WC, Jin F, Devesa S, et al. Rapid increase in colorectal cancer rates in urban Shanghai, 1972-97, in relation to dietary changes. J Cancer Epidemiol Prev 2002;7:143-146.
3. Li S, Wang J, Lu Y, et al. Screening and early diagnosis of colorectal cancer in China: a 12 year retrospect (1994-2006). J Cancer Res Clin Oncol 2007;133: 679-686.
4. Bellacosa A. Genetic hits and mutation rate in colorectal tumorigenesis: versatility of Knudson's theory and implications for cancer prevention. Genes Chromosomes Cancer 2003;38:382-388.
5. Rajagopalan H, Nowak MA, Vogelstein B, et al. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003;3:695-701.
6. Redston M. Carcinogenesis in the GI tract: from morphology to genetics and back again. Mod Pathol 2001;14:236-245.
7. Celis JE, Celis P, Ostergaard M, et al. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res 1999;59:3003-3009.
8. Zhao L, Liu L, Wang S, et al. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J Cancer Res Clin Oncol 2007;133:771-782.
9. Lees-Miller JP, Heeley DH, Smillie LB, et al. Isolation and characterization of an abundant and novel 22-kDa protein (SM22) from chicken gizzard smooth muscle. J Biol Chem 1987;262:2988-2993.
10. Nishida W, Kitami Y, Hiwada K. cDNA cloning and mRNA expression of calponin and SM22 in rat aorta smooth muscle cells. Gene 1993;130:297-302.
11. Shanahan CM, Weissberg PL, Metcalfe JC. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ Res 1993;73:193-204.
12. Shapland C, Hsuan JJ, Totty NF, et al. Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J Cell Biol 1993;121:1065-1073.
13. Shapland C, Lowings P, Lawson D. Identification of new actin-associated polypeptides that are modified by viral transformation and changes in cell shape. J Cell Biol 1988;107:153-161.
14. Shields JM, Rogers-Graham K, Der CJ. Loss of transge-lin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-indepen-dent pathways. J Biol Chem 2002;277:9790-9799.
15. Genini M, Schwalbe P, Scholl FA, et al. Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int J Cancer 1996;66:571-577.
16. Zuber J, Tchernitsa OI, Hinzmann B, et al. A genome-wide survey of RAS transformation targets. Nat Genet 2000;24:144-152.
17. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001;1:890-898.
18. Li LS, Kim H, Rhee H, et al. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 2004;4:3394-3400.
19. Shi YY, Wang HC, Yin YH, et al. Identification and analysis of tumor-associated antigens in hepatocellular carcinoma. Br J Cancer 2005;92:929-934.
20. Zhang YF, Liu L, Ding YQ. Isolation and characterization of human colorectal cancer cell subline with unique metastatic potential in the liver. J South Med Univ 2007;27:126-130.
21. Ramagli LS. Quantifying protein in 2-D PAGE solubi-lization buffers. Methods Mol Biol 1999;112:99-103.
22. Yang Z, Chang YJ, Miyamoto H, et al. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 2007;21: 343-358.
23. Koukourakis MI, Giatromanolaki A, Simopoulos C, et al. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 2005;22:25-30.
24. Galizia G, Lieto E, Ferraraccio F, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004;10:3490-3499.
25. Resnick MB, Routhier J, Konkin T, et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004;10:3069-3075.
26. Khorana AA, Ryan CK, Cox C, et al. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003;97:960-968.
27. Pei H, Zhu H, Zeng S, et al. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res 2007;6:2495-2501.
28. Stulik J, Kovarova H, Macela A, et al. Overexpression of calcium-binding protein calgranulin B in colonic mucosal diseases. Clin Chim Acta 1997;265:41-55.
29. Roblick UJ, Hirschberg D, Habermann JK, et al. Sequential proteome alterations during genesis and progression of colon cancer. Cell Mol Life Sci 2004;61:1246-1255.
30. Friedman DB, Hill S, Keller JW, et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004;4:793-811.
31. Zhang M, Volpert O, Shi YH, et al. Maspin is an angiogenesis inhibitor. Nat Med 2000;6:196-199.
32. Chen ZM, Wang HL. Alteration of cytokeratin 7 and cytokeratin 20 expression profile is uniquely associated with tumorigenesis of primary adenocarcinoma of the small intestine. Am J Surg Pathol 2004;28: 1352-1359.
33. Alaiya AA, Roblick UJ, Franzen B, et al. Protein expression profiling in human lung, breast, bladder, renal, colorectal and ovarian cancers. J Chromatogr B Analyt Technol Biomed Life Sci 2003;787:207-222.
34. Lees-Miller JP, Heeley DH, Smillie LB. An abundant and novel protein of 22kDa (SM22) is widely distributed in smooth muscles. Purification from bovine aorta. Biochem J 1987;244:705-709.
35. Lawson D, Harrison M, Shapland C. Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 1997;38:250-257.
36. Yeo M, Kim DK, Park HJ, et al. Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics 2006;6:1158-1165.
37. Prinjha RK, Shapland CE, Hsuan JJ, et al. Cloning and sequencing of cDNAs encoding the actin cross-linking protein transgelin defines a new family of actin-associated proteins. Cell Motil Cytoskeleton 1994;28:243-255.
38. Jones PA. Altering gene expression with 5-azacytidine. Cell 1985;40:485-486.
39. Yamamura H, Masuda H, Ikeda W, et al. Structure and expression of the human SM22alpha gene, assignment of the gene to chromosome 11, and repression of the promoter activity by cytosine DNA methylation. J Biochem 1997;122:157-167.
40. Hirasawa Y, Arai M, Imazeki F, et al. Methylation status of genes upregulated by demethylating agent 5-aza-2′-deoxycytidine in hepatocellular carcinoma. Oncology 2006;71:77-85.